PROTAC ER Degrader-2

PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) [1].

Product Specifications

UNSPSC

12352005

Target

Estrogen Receptor/ERR; PROTAC-Linker Conjugates for PAC

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; PROTAC; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/protac-er-degrader-2.html

Solubility

10 mM in DMSO

Smiles

CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)\C8=CC=C(OCC9=CC=C(NC([C@@H](NC([C@H](C(C)C)N)=O)CCCNC(N)=O)=O)C=C9)C=C8